Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Kunlun Capital was founded in 2015 by Zhou Yahui (Kunlun Wanwei and Opera founder). Value-oriented family office based in Singapore with $2B+ AUM. Does not manage external funds. 12-person team with 4 Partners across Singapore, China, and US.
Hardware technology, biomedicine, enterprise services, and consumer solutions. Early-stage venture in China, particularly Shanghai, Beijing, Jiangsu regions.
35 companies. Pony.ai (NASDAQ IPO, $3.48B), Cytek Biosciences (NASDAQ IPO), Biotheus (acquired by BioNTech for $800M), PingCAP (unicorn), Kopi Kenangan (unicorn).
To approach Kunlun Capital, founders should prepare a clear pitch that highlights their technology's globalization potential and localized capabilities. Interested parties can submit their pitches through the contact page or via email at admin@kunluncapital.com.
Kunlun Capital has made a recent investment on October 11, 2024, continuing its focus on technology-driven ventures. The firm maintains a robust portfolio of 35 companies, including notable exits like Pony.ai and Cytek Biosciences.
Kunlun Capital invests in Seed, Series A, Series B, and Series C stages.
You can pitch Kunlun Capital by visiting their contact page or emailing them at admin@kunluncapital.com.
Kunlun Capital focuses on sectors including AI, biotech, healthcare, SaaS, robotics, and generative AI.
Kunlun Capital typically invests between $20 million and $45 million.
Kunlun Capital primarily invests in Asia, with a strong focus on East Asia, particularly in China.
Kunlun Capital has a total fund size of $2 billion.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.